NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

全球腔靜脈過濾器市場-預測 (2021-2026)

Global Vena Cava Filters Market - Forecasts from 2021 to 2026

出版商 Knowledge Sourcing Intelligence 商品編碼 1023171
出版日期 內容資訊 英文 114 Pages
商品交期: 最快1-2個工作天內
價格
全球腔靜脈過濾器市場-預測 (2021-2026) Global Vena Cava Filters Market - Forecasts from 2021 to 2026
出版日期: 2021年07月12日內容資訊: 英文 114 Pages
簡介

預計全球腔靜脈過濾器市場將從 2019 年的 825,711,000 美元增長到 2026 年的 1,316,292,000 美元,在預期期間以 6.89% 的複合年增長率增長。

腔靜脈過濾器旨在防止手術過程中肺部發生栓塞和血栓(肺栓塞)。過濾器連接在上腔靜脈(從身體頂部到心臟的大靜脈)或下腔靜脈(從身體下半部到心臟的大靜脈)。這些過濾器是為由於各種原因無法接受抗凝治療的患者設計的。根據應用的不同,腔靜脈過濾器可以永久留置或可回收,以防止肺栓塞復發。

由於老年人口增加、久坐的生活方式和生活方式相關疾病的增加以及導致深靜脈血栓形成 (DVT) 的疾病患病率增加,未來幾年對腔靜脈過濾器的需求增加。據聯合國統計,2019年全國老年人口為7.03億。預計到 2050 年老年人口將翻一倍,達到 15 億,這很可能需要腔靜脈過濾器來解決肺部相關問題,有望促進中端市場的增長。

此外,心血管疾病患者人數的增加以及對微創技術(尤其是心血管疾病)的需求不斷增長,也將支持市場增長。據世界衛生組織 (WHO) 稱,心血管疾病是全球主要的死亡原因,估計每年導致 1790 萬人死亡。隨著越來越多的患者需要腔靜脈過濾器進行治療,這些疾病發病率的增加將推動腔靜脈過濾器市場的增長。

本報告調查了全球腔靜脈過濾器市場,並按過濾器類型/干預類型/地區分析了市場的基本結構和背景、主要促進/抑制因素以及整體市場規模趨勢展望。我們提供其他詳細趨勢、市場競爭趨勢、主要公司簡介等。

目錄

第 1 章介紹

  • 市場定義
  • 市場細分

第 2 章調查方法

  • 調查數據
  • 先決條件

第 3 章執行摘要

  • 研究亮點

第 4 章市場動態

  • 市場驅動因素
  • 市場抑制因素
  • 波特五力分析
    • 供應商談判權
    • 買方的議價能力
    • 新進入者的威脅
    • 替代威脅
    • 競爭對手之間的敵對關係
  • 產業價值鏈分析

第 5 章腔靜脈過濾器市場分析:按過濾器類型

  • 簡介
  • 永久性/不可恢復過濾器
  • 恢復過濾器

第 6 章腔靜脈過濾器市場分析:按干預類型

  • 簡介
  • 下腔靜脈濾器(最大限度使用)
  • 上腔靜脈濾器

第 7 章腔靜脈過濾器市場分析:按地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
    • 其他
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 意大利
    • 西班牙
  • 中東/非洲
    • 沙特阿拉伯
    • 以色列
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 印度尼西亞
    • 台灣
    • 泰國
    • 其他

第 8 章競爭信息

  • 競爭基準和分析
  • 近期投資和交易
  • 關鍵球員策略

第 9 章公司簡介

  • ALN International Inc.
  • Argon Medical Devices
  • B. Braun Medical Inc.
  • Contego Medical, Inc
  • Medtronic, Inc.
  • Johnson & Johnson
  • Boston Scientific Corporation
  • Cook Medical
  • Cordis Corporation
  • Bard Peripheral Vascular, Inc.
  • Straub Medical AG
目錄
Product Code: KSI061611202

The global vena cava filters market is expected to grow at a CAGR of 6.89% to reach market size of US$1,316.292 million by 2026, increasing from US$825.711 million in 2019. Vena Cava filters are designed to protect, embolism or clotting in the lungs (pulmonary embolism) during a surgical intervention. The deployment of the filters is done either through the superior vena cava (large vein from the upper part of the body to the heart) or inferior vena cava (large vein from the lower half of the body to the heart). These filters are designed to be considered by patients who cannot undergo anticoagulation due to diverse reasons. The vena cava filters are either permanently placed or are retrievable, depending on their use to prevent the recurrence of pulmonary embolism.

A surge in the geriatric population, sedentary lifestyles and lifestyle-related conditions, and higher disease prevalence leading to increased instances of Deep Venous Thrombosis (DVT) are some of the factors contributing to the increasing demand for vena cava filters in the years to come. According to the United Nations, in 2019, the geriatric population was 703 million persons, nationwide. The number of older persons is projected to double to 1.5 billion in 2050, this will fuel the market growth during the forecast period as the geriatric population is more likely to require vena cava filters to combat lung-related problems. In addition, the increasing number of patients suffering from cardiovascular conditions and the rising demand for minimally invasive techniques, especially for cardiovascular conditions, will drive the market growth. According to the World Health Organization, cardiovascular diseases are the leading cause of death globally, taking an estimated 17.9 million lives each year. The increasing incidence of such diseases will support the market growth of the vena cava filters market as more patients will require it for their treatment.

Furthermore, the favorable reimbursement policies in both developed and developing countries are also expected to increase the demand and adoption of vena cava filters in the market. Also, the advances in healthcare technology and the introduction of sophisticated devices will further propel the market growth during the forecast period.

By filter type, the retrievable filter segment is expected to hold a significant market share as patients prefer those over the Permanent filters since they can easily be retrieved once the purpose has been served. By intervention type, the inferior vena cava filters hold dominant market share, due to the presence of cases linked to the lower limb DVTs, they are in high demand and are responsible for about 90% of pulmonary embolisms. Geographically, North America and Asia Pacific regions are estimated to hold a notable market share owing to the increasing incidence of cardiovascular diseases and the rising geriatric population in the regions. The market share of Europe is expected to grow during the forecast period due to the increasing adoption of inferior vena cava filters in the country.

Growth Factors.

  • Increase in minimally invasive surgeries and advancement of medical imaging procedures.

The increase in the number of patients suffering from cardiovascular diseases is expected to drive the demand for minimally invasive surgeries, which, in turn, will increase the demand for vena cava filters in the market. The development of digital catheterization laboratories will contribute towards the advancement of medical imaging procedures, further strengthening the market growth. Also, the increasing awareness among the patients regarding these procedures will increase the demand during the next few years.

Restraints.

  • High costs.

The vena cava filters treatment is a costly treatment which makes it unaffordable for a majority of patients. The patients residing in developing countries are unable to afford this treatment due to the high procedure costs associated with this. This may restrain the market growth as many patients will not be able to go forward with this treatment which will result in decreasing the demand for the filters in the long run. This could pose a challenge for the key market players.

COVID-19 Impact on the vena cava filters market.

The Covid-19 pandemic moderately impacted the global vena cava filters market as due to the nationwide lockdown restrictions; many patients deferred their ongoing treatments to avoid public places which hampered the market growth. However, the patients who required the treatment on an urgent basis did go forward with the treatment kept the market growth stable. Also, the patients suffering from cardiovascular diseases witnessed a huge spike in numbers due to being affected by the virus, which resulted in the increasing demand for vena cava filters which in turn, resulted in balancing the market growth despite the novel coronavirus pandemic outbreak.

Competitive Insights.

The market leaders for the Global Heart Transplant Machine Market consists of ALN International, Inc., Argon Medical Devices, B. Braun Medical, Inc., Contego Medical, Inc., Medtronic, Inc., Johnson & Johnson, Boston Scientific Corporation, Cook Medical, Cordis Corporation, Bard Peripheral Vascular, Inc., and Straub Medical AG. The key players in the market implement growth strategies such as product launches, mergers, and acquisitions, etc. to gain a competitive advantage over their competitors and to remain the market leaders. For Instance, in April 2021, Argon Medical Devices launched Halo single-loop snare kits, in the United States, to provide both accuracy and reliability when retrieving and manipulating foreign objects from the cardiovascular system or hollow viscus.

Segmentation:

  • By Filter Type
  • Permanent/Non-Retrievable Filter
  • Retrievable Filter
  • By Intervention Type
  • Inferior Vena Cava Filter (Maximum use)
  • Superior Vena Cava Filter
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • Indonesia
  • Taiwan
  • Thailand
  • Others

Table of Contents

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. The threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. Vena Cava Filters Market Analysis, By Filter Type

  • 5.1. Introduction
  • 5.2. Permanent/Non-Retrievable Filter
  • 5.3. Retrievable Filter

6. Vena Cava Filters Market Analysis, By Intervention Type

  • 6.1. Introduction
  • 6.2. Inferior Vena Cava Filter (Maximum use)
  • 6.3. Superior Vena Cava Filter

7. Vena Cava Filters Market Analysis, By Geography

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. United States
    • 7.2.2. Canada
    • 7.2.3. Mexico
    • 7.2.4. Others
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. United Kingdom
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
  • 7.5. The Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. Israel
    • 7.5.3. Others
  • 7.6. Asia Pacific
    • 7.6.1. Japan
    • 7.6.2. China
    • 7.6.3. India
    • 7.6.4. Indonesia
    • 7.6.5. Taiwan
    • 7.6.6. Thailand
    • 7.6.7. Others

8. Competitive Intelligence

  • 8.1. Competitive Benchmarking and Analysis
  • 8.2. Recent Investment and Deals
  • 8.3. Strategies of Key Players

9. Company Profiles

  • 9.1. ALN International Inc.
  • 9.2. Argon Medical Devices
  • 9.3. B. Braun Medical Inc.
  • 9.4. Contego Medical, Inc
  • 9.5. Medtronic, Inc.
  • 9.6. Johnson & Johnson
  • 9.7. Boston Scientific Corporation
  • 9.8. Cook Medical
  • 9.9. Cordis Corporation
  • 9.10. Bard Peripheral Vascular, Inc.
  • 9.11. Straub Medical AG